Breast Cancer
Research activity is centered on ER-positive, HER2-negative advanced or metastatic breast cancer, with attention to disease settings where endocrine-driven growth remains a major therapeutic concern.
- Advanced breast cancer
- Metastatic disease
- Hormone receptor-positive tumors
The sponsor’s clinical focus in this area is aligned with treatment strategies for patients whose tumors depend on estrogen receptor signaling.
Endocrine-Targeted Oncology
Its therapeutic interests include estrogen receptor-directed cancer treatment, reflecting a strong emphasis on tumors driven by hormone signaling pathways.
- ER pathway modulation
- Hormone-sensitive malignancies
- Endocrine resistance
This area of work is focused on refining treatment options for cancers that remain dependent on endocrine signaling despite prior therapy.
Combination Cancer Therapy
Clinical research also covers combination approaches in oncology, with interest in pairing targeted therapy with agents used in breast cancer care.
- Targeted treatment combinations
- Pathway-based therapy
- Therapeutic tolerability
These studies are directed toward treatment settings where combining mechanisms may improve control of metastatic breast cancer.
